

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

October 14, 2003

OVERNIGHT COURIER 10/14/03

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

**Withdrawal of Petition Docket No. 02P-0478/CP1
Fentanyl Transdermal System, 12.5 mcg/hr**

Dear Sir or Madam:

Reference is made to the above-referenced petition submitted on November 4, 2002, pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act. The petition requested that the Commissioner of the Food and Drug Administration find that a change in strength for the aforementioned product was suitable for submission in an abbreviated new drug application (ANDA).

Lachman Consultant Services, Inc., respectfully requests that the petition be withdrawn.

Please contact me directly if you have any questions.

Sincerely,

Robert Pollock (BA)

Robert W. Pollock
Vice President
Lachman Consultant Services, Inc.
1600 Stewart Avenue
Westbury, New York 11590

RP/bh

cc: M. Shimer (Office of Generic Drugs)
L. Lachman

M33p3287

02P-0478

WDL 1

2156 '03 OCT 15 A9:26